fda compounding semaglutide enforcement news november 2025 GLP-1 Weight Loss Drug in 2025: State Attorneys General Step into a Growing Regulatory Gap The FDA has announced that

This was for two reasons

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

FDA prescribing information for GLP-1 medications does not list generalized skin sensitivity or heightened skin reactivity as recognized adverse effects

Blood Sugar Control : For people with Type 2 diabetes, controlling blood sugar levels is essential for a healthy pregnancy

Your prescribing clinician monitors safety and efficacy throughout treatment

The extensive research data demonstrates compelling effects on glucose regulation, appetite control, and energy metabolism, making it an invaluable tool for laboratory investigations